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In mammals, the universal sulfuryl group donor molecule
3-phosphoadenosine 5-phosphosulfate (PAPS) is synthesized
in two steps by a bifunctional enzyme called PAPS synthetase.
The APS kinase domain of PAPS synthetase catalyzes the sec-
ond step in which APS, the product of the ATP-sulfurylase
domain, is phosphorylated on its 3-hydroxyl group to yield
PAPS. The substrate APS acts as a strong uncompetitive inhib-
itor of the APS kinase reaction. We generated truncated and
point mutants of the APS kinase domain that are active but
devoid of substrate inhibition. Structural analysis of these
mutant enzymes reveals the intrasubunit rearrangements that
occur upon substrate binding. We also observe intersubunit
rearrangements in this dimeric enzyme that result in asymmetry
between the twomonomers. Our work elucidates the structural
elements required for the ability of the substrate APS to inhibit
the reaction at micromolar concentrations. Because the ATP-
sulfurylase domain of PAPS synthetase influences these ele-
ments in theAPS kinase domain, we propose that this could be a
communication mechanism between the two domains of the
bifunctional enzyme.
Enzyme inhibitors are molecules that bind to enzymes and
decrease their activity. Usually, we think of inhibitors as mole-
cules that mimic the substrates, products, or transition state or
fit in an allosteric site and, once bound, arrest the enzyme in its
catalytic cycle or slow it down. However, even the true sub-
strates (or products) of the reaction can act as inhibitors. In
such cases, enzyme kinetic measurements show pronounced
deviations from the hyperbolic dependence of velocity on sub-
strate concentration. Substrate inhibition is usually observed
only at high substrate concentrations, whereas at low substrate
concentrations the kinetics follow simple Michaelis-Menten
behavior.
Substrate or product inhibition phenomena are widely found
in nature and believed to be important for metabolic feedback
regulation processes (1–3). However, the underlying mecha-
nisms are complex and structurally poorly characterized. In this
work, we shed light on one such system present in adenosine
5-phosphosulfate (APS)4 kinase.
APS kinase is an evolutionarily conserved enzyme catalyzing
the second step in the formation of 3-phosphoadenosine
5-phosphosulfate (PAPS), the universal sulfuryl donor in bio-
logical systems. In the first reaction of PAPS formation, inor-
ganic sulfate is converted to APS by ATP-sulfurylase. In the
second reaction, APS kinase phosphorylates APS at the 3-hy-
droxyl of the ribose to produce PAPS.
ATP-Mg  SO4
2 º APS PPi-Mg ATP sulfurylase
REACTION 1
APS  ATP-Mg º PAPS ADP-Mg APS kinase
REACTION 2
PAPS is used as a substrate for sulfotransferases, which sulfon-
ate a wide rage of molecules, including proteins, glycosaminogly-
cans, steroid hormones, and xenobiotics (4). ATP-sulfurylase and
APS kinase are separate enzymes in bacteria, yeast, fungi, and
plants, but are found on a single polypeptide chain in the animal
kingdom (5). In its bifunctional form, called PAPS synthetase or
PAPSS, each domain retains the same fold as in the homologous
monofunctional enzyme (6–8). The significance of this protein
fusion is still ambiguous. Kinetic studies indicate no substrate
channeling between the domains (9), a result consistent with the
recent crystal structure of human PAPSS (8).
The importance of the reaction catalyzed by PAPSS is
emphasized by the fact that mutations in one of the two iso-
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Supplemental Material can be found at: 
forms of this enzyme (PAPSS1 and PAPSS2) significantly affect
phenotype. Mutation in isoform 2 (PAPSS2) is associated with
spondyloepimetaphyseal dysplasia disease in humans (10) and
brachymorphism in mice (11, 12).
Extensive biochemical studies on the Penicillium chrysoge-
num (13) APS kinase have revealed that this enzyme forms a
dimer in solution and follows a sequential ordered reaction
mechanism: the substrate MgATP binds before APS, and the
release of the product PAPS occurs prior to ADP (Scheme 1).
Interestingly, the P. chrysogenum APS kinase (13, 14) as well as
the Arabidopsis thaliana (15), human (9), and rat (16, 17)
enzymes have been reported to exhibit pronounced uncom-
petitive substrate inhibition by APS. Kinetic data suggest that
the inhibitory complex results from formation of the
EADPAPS complex (Scheme 1). In contrast, the APS kinase
from Escherichia coli represents a distant protein that proceeds
through a phosphorylated enzyme intermediate and exhibits
competitive substrate inhibition (18). The physiological rele-
vance of strong substrate inhibition observed in APS kinase is
still ambiguous.
Crystal structures ofAPS kinases have been characterized for
the P. chrysogenum (7, 19) and human enzymes (8, 20). For the
latter, structures both in the context of the bifunctional protein
(8) as well as of the isolated domain (20) have been reported.
The P. chrysogenum enzyme (7, 19), the isolated human APS
kinase domain of PAPSS1 (20), and the recently deposited
structure of the APS kinase domain of PAPSS2 (PDB ID 2AX4)
are found as a symmetrical dimer in the crystal, with the iden-
tical set of nucleotides present in the two monomers. In con-
trast, the crystallized bifunctional enzyme PAPSS1 (8) revealed
an asymmetrical dimer, where one subunit had ADP bound
(and APS after soaking), whereas the other subunit had no
nucleotides in the active site. This difference raised the ques-
tion of whether dimer asymmetry of the APS kinase domain in
the context of the bifunctional enzyme is a crystallization arti-
fact or a reflection of a real conformation in solution. Harjes et
al. (8) rationalized the asymmetry to be a consequence of the
differences in the P-loop sequence present in the human
enzyme versus the one in the P. chrysogenum enzyme, which
crystallized as a symmetrical dimer. However, our recent struc-
ture of the APS kinase domain from human PAPSS1 (20) shows
a symmetrical dimer, thereby eliminating the sequence differ-
ences as a possible cause for the observed asymmetry.
Our structures of the APS kinase domain also reveal that the
N-terminal region of one monomer is in close proximity to the
active site of the other monomer
(20).Wedesigned severalmutations
in this region to investigate if this
conformation is significant and if
the N termini play a role in the cat-
alytic activity of the enzyme. How-
ever, mutations of N-terminal resi-
dues closest to the active site had no
effect on the activity (20). Surpris-
ingly, it was found that, in a variant
lacking the first 50 N-terminal resi-
dues (50N), substrate inhibition
was abolished and the maximum
activity was approximately one-half compared with the full-
length enzyme. To explain this unexpected result at the molec-
ular level we solved the crystal structure of the50N-truncated
APS kinase domain variant of PAPSS1. Based on analysis of our
structure we propose a model for the regulation of substrate
inhibition that was validated by mutagenesis. Together, the
work presented herein analyzes the nature and regulation of
uncompetitive substrate inhibition observed in APS kinases,
which contributes to the understanding of substrate inhibition
per se and suggests a possible communication mechanism
between the APS kinase and ATP-sulfurylase domains in the
bifunctional PAPSS.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—The APS kinase
domain (amino acid residues 25–227) of the PAPSS1 coding
region (21) was cloned as a glutathione S-transferase fusion in
thebacterial expressionvectorpGEX-RB (22) inwhich the throm-
bin cleavage site was replaced by a tobacco etch virus (TEV) pro-
tease recognition site. The samewas done for the deletionmutant
34N-(35–227) and the pointmutants R37A andR40A (the latter
made in the background of the 25–227 construct). Proteins were
expressed and purified as described before (20).
The deletion mutant 50N-(51–227) was initially cloned in
the same vector as the other constructs, but the GST tag could
not be effectively removed from the expressed protein. To over-
come this problem, we cloned the 50–227 coding region of
human APS kinase domain in the pJC20 vector that carries no
tags. Transformed cells of the BL-21 Codon-Plus (Stratagene)
strain of Escherichia coli were induced with 0.5 mM isopropyl
1-thio--D-galactopyranoside and left to grow at 22 °C over-
night. Cells were lysed by sonication, and after centrifugation
the supernatant was subjected to ammonium sulfate precipita-
tion. Fractions precipitatedwith 40–80% of ammonium sulfate
were pooled, resuspended, and dialyzed against a buffer con-
taining 25mMTris, pH7.5, 1mMEDTA, 5mMMgCl2, and 2mM
dithiothreitol. The protein solution was applied on pre-equili-
brated Blue-Sepharose 6 Fast Flow column (Amersham Bio-
sciences), washed, and eluted with a salt gradient from 0 to 1 M
KCl. Fractions eluted with 250–400 mM KCl were collected,
merged, concentrated, and dialyzed against the same buffer as
after ammonium sulfate precipitation. The protein was further
purified by an anion exchange column (WP-QUAT, J. T. Baker,
Phillipsburg,NJ) andhighly pure50NAPSkinase eluted at 1M
KCl. Purified protein was dialyzed against 50 mM Tris, pH 7.5,
SCHEME 1. The ordered binding kinetic mechanism of APS kinase. The inhibitory complex (EMgADPAPS)
is formed after release of the product PAPS by the enzyme (E), to which APS binds prior to ADP release.
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200mMKCl, 5mMdithiothreitol, and 5% glycerol, and stored at
80 °C. During the purification process the purity of APS
kinasewas followed by SDS-PAGE.The final yield froma 2-liter
culture was8mg of protein. Prior to crystallization, the50N
APS kinase protein was dialyzed against a solution containing
25 mM Tris-HCl, pH 7.5, 25 mM KCl, and 5 mM dithiothreitol.
Crystallization and X-ray Data Collection—Crystals were
grown at room temperature using hanging drops containing
equal volumes of protein and reservoir solution (2 2 l). The
protein solution contained 3.2 mg/ml 50N APS kinase, 2 mM
dADP, 2 mM APS (or 2 mM PAPS), and 5 mM MgCl2, whereas
the reservoir contained 16–20% (w/v) polyethylene glycol 3350
and 0.25–0.15 M di-ammonium hydrogen citrate (pH 5.0). We
used dADP instead of ADP to allow unambiguous discrimina-
tion to APS, which is isosteric to ADP. Nice single crystals
appeared within 2 days and exceeded the size of 150  200 
100 m. 100%mineral oil (light white; SigmaM3516) was used
as a cryoprotectant.
Data were collected using the SER-CAT beam line at the
Advanced Photon Source, Argonne National Laboratories, and
processed with the XDS program package (23).
Steady-state Kinetics—The APS kinase enzymatic assay in
the forward reaction was performed by monitoring the rate of
ADP formation using the pyruvate kinase/lactate dehydroge-
nase-coupled spectrophotometric assay that measures the
decrease in absorbance at 340 nm due to the oxidation of
NADH.The assaywas performed using 200–400 nM enzyme in
a buffer containing 50 mM Tris-HCl, pH 7.5, 100 mM KCl, 2.5
mMMgCl2, 0.25mMEDTA, 1.0mMATP, 0.4mMphosphoenol-
pyruvate, and 0.2 mM NADH. The concentration of APS was
varied between 2 and 100 M. The reaction mixture was left to
equilibrate for 10 min at 37 °C to allow for the consumption of
trace ADP present in the ATP stock solution. APS kinase was
added to trigger the reaction. All measurements were made in
FIGURE 1. The50NAPS kinase variant is devoid of APS substrate inhibi-
tion.A, plot of initial rates as a functionofAPS concentration at constant 1mM
MgATP. Kinetic curves for the full-length wild-type-(1–227), the 34N-(35–
227), and the50N-(51–227) APS kinase constructs of humanPAPSS1 and are
shown inblack,blue, and red, respectively.B, steady-state kinetic constants for
the enzyme variants displaying substrate inhibition were obtained by fitting
the curves to the equation, v	 Vmax/(1 Km/[APS] [APS]/Ki). That lacking
substrate inhibition (i.e. 50N variant) was fitted to the Michaelis-Menten
equation. Colors correspond to those in A.
TABLE 1
Data collection and refinement statistics
dADPPAPS dADPAPS
Data collection
PDB ID 2pez 2pey
Beamline APS, SERCAT-BM APS, SERCAT-BM
Wavelength (Å) 1.000 1.000
Unit cell (Å) a	 44.09, b	 59.40, c	 139.02, 	 	 	 90 a	 43.43, b	 59.75, c	 138.92, 	 	 	 90
Space group P212121 P212121
No. molecules/a.u. 2 2
Resolution limit (Å) 30-1.40 20-1.88
Measured reflections 273,547 202,712
Unique reflections 64,712 29,201
Completeness (%; overall/last shell) 88.6/87.0a 97.1/82.7b
I/I (overall/last shell) 15.73/4.31a 16.63/4.14b
Rsymc (overall/last shell) 5.8/36.2a 9.1/42.9b
Refinement
Resolution limit (Å) 20-1.40 20-1.88
No. reflections (working/free) 57,725/6,493 26,048/2,915
Rcrystd (overall/last shell) 0.197/0.255a 0.209/0.332b
Rfree (overall/last shell) 0.220/0.302a 0.253/0.389b
No. protein/water/nucleotide residues 334/340/3 329/172/3
Root mean square deviation from ideal geometry (Å)
Bond length 0.013 0.012
Angle distances 1.937 1.487
Estimated coordinate error (Å) 0.076 0.165
Ramachandran plot statistics
Residues in most favored regions 90.8% 92.4%
Residues in allowed regions 8.2% 6.9%
Residues in generously allowed regions 1.0% 0.7%
Residues in disallowed regions 0.0% 0.0%
a Last shell (dADPPAPS)	 1.398–1.435 Å.






Fobs, 10% randomly omitted reflections were used for Rfree.
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triplicate at 37 °C using a Varian Cary 50 Bio UV-visible
spectrophotometer.
RESULTS
Deletion of the 50 N-terminal Residues from the APS Kinase
Domain of Human PAPSS1 Abolishes Substrate Inhibition—Pre-
vious work revealed that the N-terminal residues of the APS
kinase domain of PAPSS1 form an extension that interacts with
the neighboring molecule of the dimeric enzyme (20). Specifi-
cally, residues 26–35 of molecule A adopt an extended confor-
mation near to the active site of molecule B (and vice versa),
whereas residues 36–44 form a helix at the interface of the two
molecules. Although the overall amino acid sequence conser-
vation of the N-terminal region in APS kinase domains is low,
two residues are highly conserved: an invariant asparagine at
position 27, and either a glutamine or histidine at position 31.
The proximity of these N-terminal residues of one molecule to
its neighbor, together with sequence conservation at positions
27 and 31, suggested that these amino acids could be function-
ally important. To test this, point
mutations and a deletion variant
were generated. Surprisingly, the
two point mutants (N27A and
Q31A) as well as a variant lacking
the first 34 N-terminal residues
showed no appreciable effect on the
enzyme kinetics (20). In contrast,
deletion of additional 16N-terminal
residues (50N mutant) resulted in
a protein totally devoid of substrate
inhibition by APS and with approx-
imately half of the full-length’s kcat
(Fig. 1). These results prompted us
to solve the structure of the 50N
variant of the APS kinase domain to
decipher the structural reasons of
the unexpected kinetic behavior
observed for this construct. Our
goal is to understand how the pres-
ence/absence of these 16 residues
controls substrate inhibition.
Crystal Structure of 50N APS
Kinase Domain of Human PAPSS1
Reveals an Asymmetrical Dimer—
Structure of the 50N mutant of
APS kinase domain (50–227) was
solved in two different complexes.
One complex contains dADP and
APS, whereas the second has dADP
and PAPS. The use of dADP instead
of ADP in these studies allowed us
to unambiguously differentiate
between the isosteric nucleotides
ADP and APS. Crystallographic
data for the dADPAPS complex
extended to 1.88 Å, and the struc-
ture was refined to an R-factor of
20.9% and Rfree of 25.3%. The
dADPPAPS complex diffracted to 1.40 Å and was refined to
an R-factor of 19.7% and Rfree to 22.0%. Detailed data collec-
tion and refinement statistics for both complexes are sum-
marized in Table 1.
The overall fold for the truncated enzyme (Fig. 2A) is essen-
tially identical to that previously described for this domain in
the context of the intact human bifunctional PAPSS1 (8) as well
as the isolated APS kinase domain of PAPSS1 (20) and PAPSS2
(PDB ID 2AX4). However, where previously a symmetrical
dimer was observed in the structures of the isolated domains in
which both monomers had their nucleotide acceptor and
nucleotide donor sites identically occupied, the50Nvariant of
APS kinase domain revealed an asymmetric dimer. One mon-
omer has both nucleotides bound, as seen before, whereas the
second monomer has only dADP present (i.e. APS or PAPS
were absent). We observed the same asymmetrical dimer for
both the dADPAPS and dADPPAPS complexes reported here
(see supplemental data). Interestingly, asymmetry within a
dimer of the APS kinase domain has also been observed in the
FIGURE 2. The APS kinase domain consists of three rigid body parts. A, a ribbon diagram of the dimeric50N
variantof theAPSkinasedomainfromhumanPAPSS1withdADP(purple)andAPS(green) intheactivesite.Notethat
both nucleotides are present only inmolecule A, whereas the active site of themolecule B contains only dADP. The
empty phosphoryl acceptor binding site coincides with the disordered loop between helix 6 and strand 5 in
molecule B. TheRigidBody1 (RB1) region is shown in light blue inmolecule A anddark blue inmolecule B; RigidBody
2 (RB2) is yellow inmolecule A and orange inmolecule B; the APS-cap regions are pink and red inmolecules A and B,
respectively.B, schematicof the50NAPSkinasedimerpresented in the samecolor schemeas the ribbondiagram
inA. Inset, schematicofanNMPkinasemonomerdemonstrates its similarityanddifferencetothatofAPSkinase.The
three rigid bodies in NMP kinases are: lid (blue), core (yellow), andNMPbinding region (pink). C, overlay ofmolecule
AandmoleculeBof the50NAPSkinasevariantbasedonCatomsbelonging to residues thatdefineRB1.Note the
excellent overlayof RB1, and thedifferent conformationof RB2andAPS-cap.D, analogousoverlay as inCwhereC
atoms from residues belonging to RB2were used for calculating the superpositionmatrix. However, the APS-caps
do not overlaywell. Superposition of only APS-cap residues demonstrates that the APS-cap also behaves as a rigid
body (inset). Together,C andDdemonstrate the validity of dissectingAPS kinase into three rigid bodies.Colors inC
andD correspond to those in A.
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context of the human bifunctional PAPSS1 (8). In that struc-
ture, one monomer had ADP bound (and APS after soaking)
but the othermonomer’s active site remained invariably empty.
The absence of nucleotide in the phosphoryl acceptor-bind-
ing site of one monomer in our structures resulted in a flexible
lid region, inferred by the lack of electron density for residues
171–190 in that monomer (dashed line, Fig. 2A; schematically
represented as amesh pattern in Fig. 2B). Lack of electron den-
sity for this segment of the protein in the absence of APS is
consistent with prior results (8, 19). Detailed descriptions of the
interactions made by the nucleotides and the enzyme are sim-
ilar to those reported before and are presented as supplemen-
tary information (supplemental Fig. S2).
It has been noted byMacRea et al. (19) that the overall fold of
APS kinase resembles that of the nucleoside monophosphate
(NMP) kinases. These enzymes phosphorylate nucleoside
5-monophosphates (e.g. AMP and GMP) to yield nucleoside
5-diphosphates (e.g. ADP and GDP). Because APS kinase also
catalyzes phosphoryl transfer, although this time to the ribose
3-hydroxyl of APS to yield PAPS, it is not surprising that APS
kinase adopts an “NMP kinase-like” fold.
Structural studies of NMP kinases revealed that these
enzymes possess three regions named core, lid, and the NMP-
binding region. InNMPkinases, these structural and functional
elements behave as rigid bodies that change positions relative
to one another during the catalytic cycle (24–26).Wewere able
to also identify rigid regions in the APS kinase domain by com-
paring the two molecules present in the asymmetric unit: one
with only dADP bound, the second with both dADP and APS.
We included for this comparison other published structures of
the humanAPSkinase domain (8, 20). The rigid regions present
inAPS kinase (Fig. 2B) are somewhat different from those iden-
tified forNMPkinases (inset, Fig. 2B). A part thatwas attributed
to the core region in NMP kinases unites with the lid region in
APS kinase (blue colors, Fig. 2) to form a region we call Rigid
Body 1 (RB1) (Fig. 2C). The remain-
ing part of the core (yellow and
orange, Fig. 2) forms an independ-
ent rigid body that we designate as
Rigid Body 2 (RB2) (Fig. 2D). The
third rigid region in APS kinase
(inset, Fig. 2D), the analogous part
to the NMP-binding region of NMP
kinases, is labeled APS-cap and is
shown in pink/red in Fig. 2.
Comparison of the two mono-
mers present in the crystal struc-
ture of the 50N variant reveals
intramolecular differences (i.e. dif-
ferent relative orientations of RB1,
RB2, and APS-cap). These differ-
ences can be attributed to the
absence of APS in one of the mono-
mers. In addition, superpositioning
the structure of the APS kinase
domain, which exhibits APS inhibi-
tion (residues 25–227), with the
50N variant reported here, which
lacks APS inhibition, reveals intermolecular differences. The
intramolecular changes (i.e. the relative orientation of the rigid
regions within amonomer) and the intermolecular changes (i.e.
the relative orientation of the two monomers forming the
dimer) are related and are discussed in the next section.
Intramolecular Rearrangements, Closing of the Active Site—
TheAPS kinase reaction follows the sequential ordered binding
mechanism (Scheme 1) in which ATP binds prior to APS and
PAPS leaves before ADP (13). To understand the intramolecu-
lar conformational changes that occur upon nucleotide binding
we compared the nucleotide-free monomer of the APS kinase
domain as observed by Harjes et al. (8) with our 50N mono-
mer in which only dADP is present. We then added to our
analysis the second 50N monomer (monomer A) where
dADP occupies the phosphoryl-donor site and APS the accep-
tor site.
Superposition of the ligand-free APS kinase monomer and
the dADP-only monomer shows that dADP binding, used here
to approximate ATP binding, elicits only moderate conforma-
tional changes. These changes are mainly limited to the RB1
region. Specifically, rearrangements of the P-loop and the loop
connecting 5 and 8 that provides the binding pocket for the
adenine base take place. Most notably, binding of dADP orders
10 residues of the lid region (161–170), which in the absence of
nucleotides has 31 unstructured residues (161–190; see Fig. S1).
The lid residues adopt a more rigid conformation due to the
stacking interaction between Arg-168 and the adenine base of
dADP (supplemental Fig. S2). This decrease in flexibility of the
lid region is necessary for effective binding of the second nucle-
otide APS, which would explain the obligate order of binding of
this enzyme (13). Note that, although the binding of ATP with
its associated magnesium ion would also induce a change in
conformation of the DGDN-loop (for a discussion on the
impact of magnesium binding to APS kinase see Ref. 20), which
is aWalker B motif located in RB2, this change is not predicted
FIGURE 3. Residues from all three rigid body domains participate in APS binding upon which a closed
conformation is achieved. A, binding of APS (in ball-and-stick) involves residues from all three rigid body
regions: RB1 (light blue), RB2 (yellow), and APS-cap (pink). Specifically, themain chain carbonyl of Gly-184 from
RB1 interacts with the guanidinium group of Arg-106 from APS-cap. The adenine base of the APS is further
stabilized in a syn conformation through -interactions provided by aromatic amino acids Phe-185 (RB1) and
Phe-101 (APS-cap). RB2 residues contribute to APS binding by providing two NHmain-chain interactions from
residues Ile-132 and Ser-133 with the phosphate and sulfate moieties. For clarity, these interactions are omit-
ted here but are shown in supplemental Fig. S2 together with all the interactions that were observed in the
active siteofmoleculeAof50NAPSkinase.B, schematic representingamonomer in theADP-onlyboundstate
(as seen inmolecule Bof50NAPS kinase) on the left and in theADP-APS-bound state (as seen inmolecule A) on
the right. The additional presence of APS in the active site results in the complete ordering of the RB1 lid region
and in closure of the active site: the distance between the lid residue Gln-167 and APS-cap residue Ser-102
shrinks from 29 to 24 Å (green arrow).
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to dramatically impact the relative orientation of the two rigid
bodies RB1 and RB2.
Comparison of the dADP-bound APS kinase (molecule B,
Fig. 2A) and the dADPAPS-bound enzyme (molecule A, Fig.
2A) reveals that the binding of APS generates a rearrangement
of the domains RB1, RB2, and APS-cap. Interestingly, APS
makes interactions with the lid (a component of RB1), in addi-
tion to interacting with the APS-cap and residues located in
RB2 (Fig. 3A and supplemental Fig. S2). In particular, the ade-
nine base is held firmly between Phe-185 from the lid (RB1) and
Phe-101 from the APS-cap. Also, the main-chain carbonyl of
the lid residue Gly-184 establishes interactions with the amino
group of the adenine and with the APS-cap residue Arg-106,
which is bridging between the sulfuryl group and the adenine
moiety of APS. Such lid-phosphoryl acceptor interactions are
not observed in NMP kinases, where the lid residues are only
involved in phosphoryl-donor bind-
ing (usually ATP) and provide resi-
dues for phosphoryl transfer. In
APS kinase, in addition to those
roles, lid residues are engaged in the
shaping of the phosphoryl-acceptor
(APS) binding site. This property
underscores the need for ordered
binding where ATP must bind first
to initiate the positioning of lid res-
idues that would later participate in
APS binding.
Most importantly, due to the
interactions between the RB1 (lid),
RB2, and the APS-cap, binding of
APS, in addition to inducing lo-
cal conformational changes, also
changes the relative orientation of
these regions. The latter results in a
shortening of the distance between
RB1 and RB2 and thus a “closing” of
the APS kinase active site (Fig. 3B).
Most pronounced is a reduction of
the separation between the lid and
APS-cap, decreasing by 5 Å
(measured between residue 102 of
theAPS-cap and 167 of the lid; green
arrow Fig. 3B).
Intermolecular Rearrangements,
Twisting between the Monomers—
The presence of an asymmetrical
dimer in the 50N structures
prompted us to compare it to the
symmetrical dimers observed for
the slightly longer 25N variant.
We noticed that when the RB2
regions from these two crystal
structures are overlaid, the RB2
regions (RB2 designates the RB2
region of the other monomer) do
not overlay well (Fig. 4, A and B). In
contrast, if we perform the analo-
gous overlay of 50N on the asymmetrical dimer of the APS
kinase domain of human bifunctional PAPSS1 (8), the RB2
regions overlay almost perfectly. In other words, the relative
orientation of the two molecules forming the dimer is similar
between the structures that exhibited asymmetry, but different
to the symmetrical dimer.
This difference in quaternary conformation can be
described as a 15° twist, as calculated by DynDom (27),
between the two monomers that build the dimer. Although
the monomer-monomer interface includes residues from
both RB2 and the APS-cap, the twist motion involves only
RB2. The relative orientation of the two APS-caps remains
static due to the strong interactions between them (Fig. 4C).
Similar interactions that “lock” the APS-cap regions from
the twomonomers were also reported for the P. chrysogenum
APS kinase (19).
FIGURE 4. Intermolecular rearrangements in the APS kinase dimer, the RB2 domains twist while the
APS-caps remain tightly connected.A, C trace of the50NAPS kinase dimerwith the RB2 regions shown in
orange, and the APS-cap regions from molecules A and B in pink and red, respectively. The RB1 regions are
shown as transparent blue objects. Helix4 of the RB2 region is shown as a thicker object. The corresponding4
helices as observed in the structure of the full-length PAPSS1 (magenta) and in the 25N APS kinase variant
(black) are superimposed. B, close-up view of helices4 from the RB2 regions belonging to the twomonomers
that build the dimer. The overlay was done based only on C atoms in the helix belonging to molecule A. A
twist between two 4 helices from asymmetrically crystallized complexes (50N APS kinase (orange) and
full-length PAPSS1 (magenta)) is obvious in comparison to the symmetrically crystallized 25N APS kinase
(black). For clarity we show only the 4 helices, but the twist affects the entire RB2 region. C, a perpendicular
view to the interactionsmaintained between the APS-cap regions belonging tomolecules A and B. Intramolec-
ular salt bridges are shownaspink and red dotted lines, whereas thosemadebetween the twomonomers are in
black. Hydrophobic interactions across the dimer interface (specifically -interactions between the guani-
diniumgroups of arginines 112 and between the C atomof Arg-112 and C atomof Leu-95) are presented as
black arrows with the corresponding distances in Å. D, schematic representation of the dimer interface com-
posed of the RB2 regions and APS-caps. The distance between the APS-cap of monomer A and that of mono-
mer B, asmeasuredwith respect to Ser-102, is the same in both the symmetrical and asymmetrical dimer (25
Å). In the symmetrical dimer thedistancebetweenAPS-cap residue Ser-102 andRB2 residue Ile-132 is the same
in bothmonomers (13 Å). In contrast, in the asymmetrical50N dimer, it increases by3 Å. This increase in
distance is a consequence of the RB2 domain twisting.
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As a consequence of this movement, RB2 shifts away from
the APS-cap (see schematic, Fig. 4D). The RB2-APS-cap sep-
aration, as measured between residues 132 (RB2) and 102
(APS-cap), increases by3 Å. Because APS binding requires
residues from both the APS-cap and RB2 regions, the result-
ing conformation of this monomer has a distorted APS-
binding site.
Role of the 1 Helix—As was mentioned before, deletion of
the first 34 N-terminal amino acids results in an enzyme with
similar kinetic behavior to the full-length domain, whereas
deletion of additional 16 residues (50N construct) yields an
enzymedevoid of substrate inhibition.We focused on the inter-
actions established by these 16 residues (shown as a thick green
ribbon in the Fig. 5A) to understand how these residues are
involved in APS substrate inhibition.
The most prominent structural
element constructed by these res-
idues is helix 1. Interestingly,
although most of the residues
comprising this helix are not con-
served, two arginines are strictly
conserved: Arg-37 and Arg-40
(Fig. 5B). Arg-37 forms salt
bridges with two RB2 residues
from the same monomer: the side
chain of Asp-122 and main-chain
carbonyl of Ser-150. On the other
hand, Arg-40 forms a salt bridge
with the side chain of Glu-73,
which is an RB1 residue from the
opposite monomer (Fig. 5C). Thus,
helix 1 arginine residues build
ionic interactions between RB1 of
the one molecule and RB2 of the
other molecule. Because the rela-
tive orientation of RB1 to RB2
changes upon APS binding (see
intramolecular movements above),
and because helix1 connects these
two regions, albeit between neigh-
boring molecules, we speculated
that the absence of these interac-
tions in the 50N enzyme could
rationalize the lack of APS inhibi-
tion of the truncated enzyme.
To explore this possibility we
mutated each of these arginines to
alanine in the full-length back-
ground and kinetically character-
ized these mutants (Fig. 6). Con-
sistent with our model, the R37A
and the R40A mutants did not
show APS inhibition, and were, in
fact, kinetically indistinguishable
from the 50N variant. This dem-
onstrates that the interactions
established by arginines 37 and 40
are indispensable for maintaining
substrate inhibition of the APS kinase domain in human
PAPSS1.
DISCUSSION
APS kinases are characterized by having an ordered
sequential mechanism and a strong substrate inhibition of
APS (9, 13, 15, 17) (see Scheme 1). Our previous work (20) on
the isolated APS kinase domain of human PAPSS1 revealed
that the N terminus of one molecule approaches the active
site of the second molecule that builds the functional
dimeric enzyme. Protein engineering experiments probing
for the exact function of these N-terminal amino acids
revealed that residues 36–50 are required for the APS sub-
strate inhibition. To understand why the lack of these resi-
dues abolishes substrate inhibition, we solved the crystal
FIGURE 5.Helix1 plays a critical role in stabilizing a symmetrical dimer. A, overlay of the symmetrical
25N and asymmetrical 50N dimer of APS kinase based on the C atoms from the RB2 domain of
molecule A. Rigid body regions of the 50N variant are colored as in Fig. 2, while monomers A and B of the
25N enzyme are in light and dark green, respectively. The slight differences between molecules A show
that the closed conformation of the symmetrical dimer is somewhat more closed than that in the asym-
metrical dimer. The large differences between molecules B shown are a result of the opening of the
molecule due to the lack of APS in the 50N structure, and of the ensuing twist motion of this molecule’s
RB2 region. B, sequence alignment of the N-terminal region present in several bifunctional (HUM_1,
human PAPSS1;MOU_1, mouse PAPSS1; XENTR, Xenopus tropicalis PAPSS; HUM_2, human PAPSS2; BRARE,
Brachydanio rerio PAPSS; URECA, Urechis caupo PAPSS; CIOIN, Ciona intestinalis PAPSS; DROME, Drosophila
melanogaster PAPSS; and CAEEL, Caenorhabditis elegans PAPSS) and monofunctional (PENIC, P. chrysoge-
num) APS kinases. Residues present in the 34N construct but missing from the 50N construct are
highlighted in green. Note the low conservation in this area with the exception of the two arginine
residues, Arg-37 and Arg-40, in the helix 1. C, stereo representation showing the interactions of arginines
37 and 40. Arg-40 from the 1 helix belonging tomolecule B interacts with the carboxylic group of Glu-73
from the RB1 ofmolecule A. Arg-37 frommolecule B, on the other hand, makes bidentate interactions with
main-chain carboxyls of Ala-149 and Ser-150, as well as with the carboxyl moiety of the Asp-122, all
belonging to RB2 of the same molecule (molecule B). In this way, helix 1 of molecule B connects RB1 of
molecule A and RB2 of molecule B. Residues are labeled with one-letter code and sequence number. Chain
designation is noted in parenthesis.
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structure of a 50N variant of the APS kinase domain in
complex with dADP and APS and with dADP and PAPS.
The first surprising finding was that this N-terminally trun-
cated enzyme crystallized in an asymmetric fashion, where
molecule A had both nucleotides present (i.e. dADP andAPS or
PAPS), whereas molecule B contained only dADP. This was
unexpected, because the previously reported structures of the
APS kinase domain of PAPSS1 (20) (residues 25–227) and
PAPSS2 (residues 21–218; PDB ID 2AX4) crystallized in a sym-
metric fashion. We asked if the observed asymmetry in the
structure could be a direct consequence of the absence of the
N-terminal residues. To answer this, we first performed an
analysis of the rigid domains present in APS kinases. We com-
pared the conformation of the ligand-free monomer (8) to that
where only dADP is bound (monomer B, Fig. 2), and finally to
where both dADP andAPS are bound (monomerA, Fig. 2). This
analysis identified the three rigid body domains that build each
APS kinase monomer, termed RB1, RB2, and APS-cap. These
domains change their relative orientation in response to the
binding of the nucleotides. In addition to these intramolecular
changes, we identified a change in the quaternary structure of
theAPS kinase dimer. In otherwords, the relative orientation of
the two monomers that form the symmetrical dimer (20) is
different to that of the asymmetrical dimer (Ref. 8 and that
reported here). We propose that this difference has ramifica-
tions on the ability of the enzyme to utilize both active sites
simultaneously (see below).
Comparison of the nucleotide-free enzyme with the dADP-
bound form reveals that the binding of nucleotide at the phos-
phoryl donor site primes the lid region to complete its addi-
tional role of complexing APS. In the absence of this priming,
APS cannot bind to the enzyme.Notably, according to our anal-
ysis, binding of nucleotide to the phosphoryl donor site of the
apo-enzyme does not significantly alter the relative orienta-
tions of the rigid bodies.
Upon subsequent APS binding at the cleft between the lid
and APS-cap, the entire lid region becomes ordered. Addition-
ally, the whole RB1 domain and the APS-cap move closer to
RB2 as APS stabilizes a more closed conformation. Thus, bind-
ing of APS involves interactions from all three rigid bodies
(RB1, RB2, and APS-cap) and results in their reorientation
within the monomer.
Overlay of the symmetrical APS kinase dimer (20) on the
here reported asymmetrical dimer reveals a slightly different
inter-monomer orientation. This difference, which we refer to
as a twist, affects the whole RB2 region. The APS-cap also
makes numerous intermolecular interactions. In contrast to the
RB2 region, the relative orientation of the two APS-caps is
maintained regardless of themolecules forming a symmetric or
asymmetric conformation.
With this information, we can address the question of why
the 50N variant displays the asymmetrical dimer whereas
the full-length enzyme adopts a symmetric form. The trun-
cated enzyme is missing helix 1. This helix in the full-length
enzyme connects the RB2 region of the monomer that it is a
part of, and the RB1 of the other monomer (Fig. 7A). In its
absence, the coupling between RB1-RB2 (and RB1-RB2) is
lost, and this allows the RB2 region of one monomer to twist
relative to the other monomer. The twist motion results in
an opening of one monomer in the dimer, where the relative
distance between RB1 and RB2 is increased. As a result of
this opening of the monomer, the affinity for APS is dimin-
ished. In total, the twist allows for only one monomer to have
both nucleotides bound in the active site, and the other mon-
omer has just the nucleotide in the phosphoryl-donor bind-
ing site. The ultimate result therefore is an asymmetrical
dimer (Fig. 7B, panel i).
In the abovemodel, we propose a coupling function between
the two monomers carried out by the 1 helix. Analysis of the
structures revealed that two conserved arginines in the helix
play an important part here: Arg-37 connects the 1 helix to its
RB2 domain, whereas Arg-40 connects it to the RB1 of the
second monomer. Indeed, mutating these arginines into ala-
nines totally abolishes substrate inhibition, consistent with the
predicted role for these residues.
The lack of intermolecular interactions provided by helix
1 serves to explain the lack of substrate inhibition as well as
reduced kcat of the truncated APS kinase variant. In enzyme
species containing helix 1 with arginines 37 and 40, a sym-
metrical dimer can be formed where all four nucleotide-
binding sites can be occupied simultaneously. In such a sit-
uation, the inhibitory ADPAPS complex can be formed in
each of the monomers (Fig. 7A). Upon deletion of the helix
(i.e. 50N variant), or uponmutation of the critical arginines
in this helix (i.e. R37A or R40A), the stabilizing function of
this region is lost. The result is a twisting motion of RB2
regions in a dimer. However, the tight interactions connect-
FIGURE 6. The R37A and R40A mutants, like the 50N construct, are
devoid of substrate inhibition. A, initial rates for the full-length (black),
50N (red), R37A (cyan), and R40A (green) APS kinase of human PAPSS1 are
shown as a function of APS concentration at constant 1mMMgATP. Note that
for comparison purposes the curves for the full-length and 50N constructs
are duplicated from Fig. 1. B, steady-state kinetic constants for the four
enzyme variants were obtained by fitting to the equations as in Fig. 1. Colors
correspond to those in A.
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ing the two APS-caps do not allow the APS-cap region to
move in concert with the RB2 regions. Therefore, the APS-
binding site in one monomer is distorted and we observe no
APS in that site (Fig. 7B, panel i).
An important consequence of the diminished APS affinity in
the twisted monomer, and hence the absence of APS, is that
now ADP can easily leave this monomer (Fig. 7B, panel ii).
Remember that, due to the ordered bindingmechanism of APS
kinase, APS release must occur before ADP can leave. The now
nucleotide-free monomer is able to bind its first substrate ATP
(Fig. 7B, panel iii). Subsequent binding of the second substrate
APS attracts the APS-cap region so that a closed conformation
forms. However, because the two APS-cap domains are tightly
connected and RB2s are twisted, this closure in one monomer
elicits a concomitant opening in the adjacent monomer. The
now distorted APS-binding site in the previously closed mono-
mer allows for APS dissociation from that monomer (Fig. 7B,
panel iv).
To summarize our structural model, a dimer lacking a func-
tional helix 1 cannot simultaneously bind all four nucleotides
(two per monomer). In other words, the APS/PAPS-binding
site can only be fully formed in one monomer at a time. The
above model of the 50N-construct implies that the two active
sites cannot be catalytically competent at the same time, just as
they cannot be inhibited at the same time. Kinetic data showing
that the kcat of the50N-variant is approximately half of the kcat
observed for the constructs having an intact helix 1, along
with the lack of APS inhibition, support the proposed single-
piston model.
The asymmetrical APS kinase dimer conformation we see
for the 50N enzyme may be physiologically relevant based
on the observation of similar asymmetry of the APS kinase
domain in the context of the bifunctional PAPSS1 (8). For
the bifunctional enzyme, asymmetry appears to be induced
by interactions of an APS kinase monomer with an ATP-
sulfurylase monomer. These interdomain (i.e. APS kinase
with ATP-sulfurylase) interac-
tions prohibit Arg-40 of the APS
kinase domain from fulfilling its
stabilizing role. Hence this mono-
mer is subject to a similar twisting
motion that we identified for the
50N APS kinase construct. The
end result is a more open mono-
mer that is not competent for
nucleotide binding.
In summary, our studies of the
50N APSK variant of human
PAPSS1 reveal the structural ele-
ments involved in potent APS sub-
strate inhibition and advance a
model for its regulation. Further-
more, our analysis suggests that the
ATP-sulfurylase domain can act to
modulate the activity of the APS
kinase domain by interactions that
affect the function of helix 1 of the
kinase domain. So, although the
crystal structure of the intact PAPSS1 does not support sub-
strate channeling between the two enzyme domains, our results
suggest a model for pronounced communication between
domains.
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